Boulet, Louis-Philippe http://orcid.org/0000-0003-3485-9393
Lavoie, Kim L.
Raherison-Semjen, Chantal
Kaplan, Alan
Singh, Dave
Jenkins, Christine R. http://orcid.org/0000-0003-2717-5647
Funding for this research was provided by:
Novartis Pharma AG
Article History
Received: 27 May 2022
Accepted: 29 September 2022
First Online: 20 December 2022
Competing interests
: L.P.B. reports research grants, consulting fees and honoraria from AstraZeneca, GlaxoSmithKline, Merck, Novartis, and Sanofi-Regeneron; research grants from Amgen and Biohaven; and honoraria from Covis, Cipla and Novartis all outside the submitted work. K.L. reports consulting fees and honoraria from AstraZeneca, Novartis, GlaxoSmithKline, AbbVie, Boehringer Ingelheim; consulting fees from Baucsh and Sojecci Inc; and honoraria from Astellas, Janssen, xFacto, Respiplus, outside the submitted work. C.R.S. reports grants and personal fees from Novartis, Chiesi, and AstraZeneca; and personal fees from GlaxoSmithKline, outside the submitted work. A.K. reports personal fees from AstraZeneca, Behring, Boehringer Ingelheim, Cipla, Covis, GlaxoSmithKline, Merck Frosst, Novartis, NovoNordisk, Pfizer, Sanofi-Genzyme, Teva, Trudel, and Valeo. D.S. reports personal fees from Aerogen, AstraZeneca, Boehringer Ingleheim, Chiesi, Cipla, CSL Behring, Epiendo, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Kinaset, Menarini, Novartis, Pulmatrix, Sanofi, Synairgen, Teva, Theravance, and Verona, outside the submitted work. C.J. reports personal fees for advisory board participation and educational content from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Sanofi-Genzyme; writing support from Novartis, and grant funding from GlaxoSmithKline, outside the submitted work.